Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
CD19-Directed Monoclonal Antibody (Fc-Enhanced)

Tafasitamab

Brand names: Minjuvi

Tafasitamab is an Fc-modified anti-CD19 monoclonal antibody used with lenalidomide for relapsed or refractory diffuse large B-cell lymphoma in patients not eligible for autologous stem-cell transplant.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds CD19 on B-cells and enhances antibody-dependent cellular cytotoxicity and phagocytosis, leading to depletion of malignant B-lymphocytes.

Prescribing in practice

  • Infusion-related reactions can occur, particularly with the first infusion, so premedication and close monitoring during administration are required.
  • Causes myelosuppression, especially neutropenia and thrombocytopenia, mandating regular blood counts when given with lenalidomide.
  • Prior anti-CD19 therapy may affect efficacy; confirm the treatment history and follow the combination schedule with lenalidomide as licensed.

Monitoring

Monitor full blood count regularly and observe closely for infusion-related reactions and infection.

Counselling the patient

  • Report any reaction during or shortly after the infusion, such as fever, chills, or breathlessness.
  • Report signs of infection, bruising, or bleeding promptly.
  • Attend scheduled blood tests and infusion appointments.

Evidence & guidelines

Tafasitamab plus lenalidomide for diffuse large B-cell lymphoma is supported by the L-MIND study and licensed for transplant-ineligible patients.

Reference: L-MIND trial (Salles et al. Lancet Oncol 2020); NICE TA739; MHRA SPC Minjuvi; RE-MIND2 study (Duell et al. Haematologica 2021); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Pathways